Why the study?
Whether restoring rigidity sensing via Tpm2.1 re-expression can fully trigger anoikis remained unclear.
Restoring rigidity sensing via Tpm2.1 sensitizes metastatic breast cancer cells to targeted therapies against Akt, EphA2, or ICAM1, revealing actionable vulnerabilities to eliminate detached tumor cells.
May sensitize detached breast cancer cells to Akt/EphA2/ICAM1 inhibition; hypothesis-generating in animal models and leaves open clinical translation.
Rigidity sensing enables cells to respond to extracellular matrix stiffness and governs survival and apoptotic decisions. Tropomyosin 2.1 (Tpm2.1), a key actin-binding protein, is frequently downregulated in cancer. While re-expressing Tpm2.1 restores rigidity sensing and limits anchorage-independent growth, its ability to fully trigger anoikis, apoptosis induced by loss of matrix attachment, remains unclear. Here, we show that although Tpm2.1 overexpression reduces Akt activation and suppresses survival signaling in suspended breast cancer cells, most cells remain viable without matrix attachment. Time-resolved transcriptomic profiling of apoptotic and non-apoptotic suspended cells revealed compensatory survival programs, including reactivation of PI3K-Akt signaling and upregulation of intercellular adhesion molecules such as ICAM1. Importantly, anoikis resistance can be overcome. Pharmacological inhibition of Akt, EphA2, or ICAM1 in Tpm2.1-expressing cells significantly increases apoptosis under suspension conditions. These findings highlight that while rigidity sensing restoration alone may be insufficient to induce anoikis, it sensitizes cancer cells to targeted therapies, revealing actionable vulnerabilities to eliminate detached tumor cells.
No takes yet. Share an insight, caveat, or question.
Vivante et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: